



# Rigel Assumes Development Responsibility

Monday, April 04, 2011 - 08:00am

Pfizer to Sell Capsugel to KKR

[http://www.pfizer.com/news/press\\_releases/pfizer\\_press\\_releases.jsp#guid=20110404005842e](http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20110404005842e)

**April 29, 2011** - Critical Path Institute Announces Expansion of Regulatory Science Consortium For Tuberculosis <http://c-path.org/News/CPTRExpansionPR.pdf>

ORIGINALLY PROVIDED IMAGE PDF. It would be great if we could get text for this release and create a pdf with it so that it becomes searchable by Search Engines.

**April 6, 2011**, Nuron Biotech Inc. acquired assets relating to HibTITER® [http://www.nuronbiotech.com/wp-content/uploads/2011/09/hib\\_Press.pdf](http://www.nuronbiotech.com/wp-content/uploads/2011/09/hib_Press.pdf)

ORIGINALLY PROVIDED IMAGE PDF. It would be great if we could get text for this release

and create a pdf with it so that it becomes searchable by Search Engines. **April 20, 2011** — Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership

[http://www.pfizer.com/news/press\\_releases/pfizer\\_press\\_releases.jsp#guid=20110420006362e](http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20110420006362e)

**April 7, 2011** - Zacharon Announces Collaboration with Pfizer to Develop Drugs for Multiple Rare Diseases.

<http://www.zacharon.com/pages/news/downloads/ZacharonPfizerPressReleas4711.pdf>

**June 02, 2011** — Pfizer and Hisun Sign MOU to Increase Access to Quality and Low-Cost Medicines for Patients in China

[http://www.pfizer.com/news/press\\_releases/pfizer\\_press\\_releases.jsp#guid=20110602005965e](http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20110602005965e)  
=RSS\_2011&page=6

**June 2, 2011** - Clovis Oncology, Inc. Receives License for Worldwide Development and Commercialization Rights to Pfizer's Oral and IV PARP Inhibitor PF-01367338

[http://www.clovisoncology.com/pdf/Pfizer\\_Clovis\\_Press\\_Release\\_6-2-11.pdf](http://www.clovisoncology.com/pdf/Pfizer_Clovis_Press_Release_6-2-11.pdf)

**May 10, 2011** - Cellzome announced joint project with Pfizer's Pain & Sensory Disorders and regenerative Medicine unit 'Neusentis',

[http://www.cellzome.com/files/1105\\_neusentis.pdf](http://www.cellzome.com/files/1105_neusentis.pdf)

**May 9, 2011** - Inhibitex, Inc. Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study

<http://markets.financialcontent.com/ir/?Module=MediaViewer&GUID=18394647&Ticker=INHX>

**May 6, 2011** - Rigel Pharmaceuticals, Inc. Rigel Assumes Development Responsibility for Inhaled Asthma Therapy <http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1560748&highlight=>

**May 10, 2011** - Foundation for the National Institutes of Health launches trial to develop diabetes Diagnostic tools

[http://www.biomarkersconsortium.org/press\\_release\\_diabetes\\_diagnostic\\_tools.php](http://www.biomarkersconsortium.org/press_release_diabetes_diagnostic_tools.php)

**June 9, 2011** Q Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs <http://phx.corporate-ir.net/phoenix.zhtml?c=197881&p=irol-newsArticle&ID=1572529&highlight=>

**The following PR (10/10) mentions Pfizer October 10, 2011** - Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs

<http://phx.corporate-ir.net/phoenix.zhtml?c=197881&p=irol-newsArticle&ID=1613922&highlight=>

**June 14, 2011** - pSivida and Pfizer Amend Agreement to Focus Solely on Development of Sustained Release Implant to Deliver Latanoprost for Ocular Hypertension and

Glaucoma <http://phx.corporate-ir.net/phoenix.zhtml?c=168274&p=irol-newsArticle&ID=1573632&highlight=>

**June 14, 2011** - pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma

<http://phx.corporate-ir.net/phoenix.zhtml?c=168274&p=irol-newsArticle&ID=1573632&highlight=>

**July 5, 2011** - DNA Electronics' point of care prototype performs well in pilot study with Imperial College and Pfizer

[http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news\\_5-7-2011-9-44-25](http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_5-7-2011-9-44-25)

**June 28, 2011** - BioPontis Alliance Enters Translational-Technology Development Agreement with Pfizer <http://www.biopontisalliance.com/news.html>

**July 5, 2011** - Cell Signaling Technology, Inc. Grants a Patent License to Pfizer [http://www.cellsignal.com/about/press/2011\\_0605.html](http://www.cellsignal.com/about/press/2011_0605.html)

**July 07, 2011** — Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition Businesses [http://www.pfizer.com/news/press\\_releases/pfizer\\_press\\_releases.jsp#guid=201107070057777er](http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=201107070057777er)

**August 29, 2011** - Jennewein Biotechnologie and Pfizer Nutrition Collaborate on Human Milk Components [http://www.jennewein-biotech.de/0811\\_Jennewein\\_Pfizer\\_Nutrition\\_Cooperation.pdf](http://www.jennewein-biotech.de/0811_Jennewein_Pfizer_Nutrition_Cooperation.pdf)

**August 16, 2011** - QIAGEN and Pfizer partner to develop companion diagnostic for novel compound in global clinical trials for lung cancer <http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=358&lang=en>

**August 3, 2011** - Biotica regains worldwide rights to its rapamycin analogue program Biotica Technologoy Ltd. [http://www.biotica.com/index.php/biotica/news\\_article/biotica\\_regains\\_worldwide\\_rights\\_to\\_its\\_rapamycin\\_analogue\\_program](http://www.biotica.com/index.php/biotica/news_article/biotica_regains_worldwide_rights_to_its_rapamycin_analogue_program)

**September 28, 2011** - International Structural Genomics Consortium Announces \$48.9 MILLION in Additional Funding to Continue the Search for New Medicines / Consortium also Welcomes Two New Member Companies [http://www.thesgc.org/sites/default/files/SGC\\_PhaseIII\\_PR\\_FINAL\\_%20for\\_release\\_110928\\_v110928.pdf](http://www.thesgc.org/sites/default/files/SGC_PhaseIII_PR_FINAL_%20for_release_110928_v110928.pdf)

**September 29, 2011** - Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept Trials <http://phx.corporate-ir.net/phoenix.zhtml?c=197881&p=irol-newsArticle&ID=1611349&highlight=>

**Oct.3,2011**- MedImmune, the global biologics arm of AstraZeneca, today announced execution of an inlicensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody. <http://pressroom.medimmune.com/press-releases/2011/10/03/medimmune-in-licenses-cancerimmunotherapy-tremelimumab-from-pfizer/>

**October 4, Pfizer Oncology/legacy-Serenex** **October 05, 2011** — Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor [http://www.pfizer.com/news/press\\_releases/pfizer\\_press\\_releases.jsp#guid=20111005006762er](http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20111005006762er)

**March 3, 2011** –Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has entered into a marketing and distribution agreement with Pfizer Inc <http://www.criver.com/en-US/NewsEvents/PressReleases/Pages/Pfizer.aspx>

**October 12, 2011** deCODE Announces Agreement with Pfizer to Search for Variants in the Human Genome that Confer Risk of Systemic Lupus Erythematosus.  
<http://www.decode.com/news/news.php?story=156>

**October 10, 2011** Exonhit enters into Research Agreement with Pfizer to identify Alzheimer's disease biomarkers  
[http://www.exonhit.com/sites/default/files/PR\\_Pfizer\\_EHT\\_7Q10Q2011\\_EN.pdf](http://www.exonhit.com/sites/default/files/PR_Pfizer_EHT_7Q10Q2011_EN.pdf)

April 4, 2011 - Oxford BioMedica Broadens 5T4 Antibody Collaboration With Pfizer  
<http://www.oxfordbiomedica.co.uk/page.asp?pageid=59&newsid=288>

**October 14 2011** DiaGenic ASA [OSL:DIAG] today reports preliminary positive findings from the collaborative R&D project with Pfizer Inc. where the objective is to identify blood-based biomarkers that may be useful in diagnosing and monitoring of Alzheimer's Disease (AD).

[http://www.diagenic.com/en/investor\\_relations/press\\_releases/Findings+from+DiaGenic%2C+Pfizer+based+Test+f.9UFRrQ2R.ips](http://www.diagenic.com/en/investor_relations/press_releases/Findings+from+DiaGenic%2C+Pfizer+based+Test+f.9UFRrQ2R.ips)